Navigation Links
MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting

al and repeat courses of moderately and highly emetogenic cancer chemotherapy and for the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. Aloxi is the first and only

5-HT3 receptor antagonist to be indicated for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) caused by moderately emetogenic cancer chemotherapy. In clinical trials, the most common adverse reactions related to Aloxi were headache (9%) and constipation (5%). Aloxi is contraindicated in patients known to have hypersensitivity to the drug or any of its components. Please see the Aloxi package insert, available at www.mgipharma.com and www.aloxi.com, for important additional details.

About Dacogen(R) For Injection

Dacogen is approved by the U.S Food and Drug Administration for the treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British (FAB) subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia), and Intermediate-1, Intermediate-2, and High-Risk International Prognostic Scoring System

(IPSS) groups. Dacogen may cause fetal harm when administered to a pregnant woman. Women of childbearing potential should be advised to avoid becoming pregnant while using Dacogen. Men should be advised not to father a child while receiving treatment with Dacogen and for 2 months afterwards. In clinical trials, the most commonly occurring adverse reactions included neutropenia (90%), thrombocytopenia (89%), anemia (82%), pyrexia (53%), fatigue (48%), nausea (42%), cough (40%), petechiae (39%), constipation (35%), and diarrhea (34%). Pl
'"/>




Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment

Post Your Comments:
(Date:11/6/2009)...a., Nov. 6 In consultation with th...Consumer Healthcare, Division of McNEIL-PPC, Inc.,...ber of product lots of TYLENOL® Arthritis Pai...ed EZ-OPEN CAP. McNeil is initiating the recall af... associated with these lots that led to a small nu...
(Date:11/6/2009)...wswire/ -- Repossessions and liquidations of truck...er of 2009 declined as compared to similar figures... NasTrac Quarterly Index (NQI). The figures, cull...possessions and orderly liquidations, also indicat...nd printing equipment, offering mixed news on the ...
(Date:11/6/2009)...ewswire-FirstCall/ -- Derma Sciences, Inc. (OT...und care products, announced plans to release its ..., November 16, 2009. The Company will hold a confe... 11:00 am EST. Interested parties should call (866...onal), with passcode 81416481 to access the call. ...
Breaking Medicine Technology:McNeil Consumer Healthcare Announces Voluntary Recall of Certain Lots of TYLENOL(R) Arthritis Pain 100 Count with EZ-OPEN CAP 2NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 2NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 3NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 4Derma Sciences Announces Date of Its Third Quarter 2009 Earnings Release and Conference Call 2Just Released New Poll 3A Healthcare Through Womens Eyes 60259 1Just Released New Poll 3A Healthcare Through Womens Eyes 60259 2Webmedx Reacts to News of Confidential Medical Records Being Sold on the Black Market 60255 1Webmedx Reacts to News of Confidential Medical Records Being Sold on the Black Market 60255 2VitaminSpice Appoints Dr Richard F Seelig as Director 5795 1VitaminSpice Appoints Dr Richard F Seelig as Director 5795 2
...25 Findings from an international,multicenter, ra... trial,evaluating ustekinumab (CNTO 1275) in the t...ll be presented for the first time at the 21st mee...akes place from Sept. 30 to,Oct. 5, 2007 in Buenos...O 1275 (anti-IL-12/23p40) Treatment of,Psoriasis: ...
...Drug,s Benefit, Alone and With Lipitor(R), in, O...and Triglycerides -, HAYWARD, Calif., Sept. 25 M...to the discovery and development of novel,therapeu... announced today,that it has begun a 180-patient P...tients with high cholesterol and triglycerides to ...
Other Medicine Technology:Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting 2Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia 2
(Date:11/8/2009)... Pharmaceutical Researc... President Ken Johnson released the following stat... ,, "We are disappointed, but not surprised by ...f hardworking Americans as well as nearly half of ...ho voted against the bill. ,, "While well inten...
(Date:11/8/2009)...Shows Who Sides With Working Families vs. Insuranc...wire-USNewswire/ -- On the heels of an historic la...a good, balanced health care reform bill, the Penn...tate,s U.S. representatives voted on HR 3962, the ... legislation, which passed Saturday evening by a v...
(Date:11/7/2009).... 7 Speaker Nancy Pelo...R. 3962, the Affordable Health Care for America Ac...onight. Below are the Speaker,s remarks. ,, "...ic moment for our nation and for American families...d political philosophy -- as far back as Teddy Roo...
(Date:11/7/2009)...RNewswire/ -- Calling this a "defining moment" for...resident J. James Rohack, M.D., today addressed me...e and medical specialty societies at the opening o...re health system reform will top the agenda. ,,...1209/AMALOGO ) ,, "Over the next 72 hours, th...
(Date:11/7/2009)... The U.S. bishops Novem...s to vote for the Stupak-Ellsworth Amendment to th...Pitts-Kaptur-Dahlkemper-Lipinski-Smith Amendment w...funding and conscience protections in the Affordab...said. ,, The letter was signed by Cardinal Just...
Breaking Medicine News(10 mins):Health News:PhRMA Statement on House Passage of Health Care Reform Bill 2Health News:PhRMA Statement on House Passage of Health Care Reform Bill 3Health News:Robert Brady (D-PA-1), Chaka Fattah (D-PA-2), Kathy Dahlkemper (D-PA-3), Joe Sestak (D-PA-7), Patrick Murphy (D-PA-8), Christopher Carney (D-PA-10), John Murtha (D-PA-12), Paul Kanjorski (D-PA-11), Allyson Schwartz (D-PA-13), Mike Doyle (D-PA-14) Ge 2Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 2Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 3Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 4Health News:AMA President Kicks Off AMA Meeting Focused on Health Reform 2Health News:Bishops Urge Passage of Stupak-Ellsworth Anti-Abortion Amendment for Health Reform Bill 2
... Five Cleveland attorneys from Spangenbe...Ohio Super Lawyers . This honor, by the much respe...aw firm,s expertise in personal injury cases and a...wyers representing personal injury and medical ma...
...aphy (SHG), a simple ultrasound technique commonly... diagnostic capability of transvaginal ultrasound ...n of the uterus that causes dysmenorrhea, abnormal...uded 26 women who underwent sonohysterography and ...
... IntelliSoft Group has released Version ...leading provider of medical credentialing software...ts that enable healthcare professionals to be more...nced the release of version 9.0 of their IntelliCr...
...ut from undamaged areas to compensate, study finds...When macular degeneration causes one to start losi...tart seeking visual input from other, non-affected...nge. Neurons seem to want to receive input: When t...
..., N.C. Researchers at Wake Forest University Bapt...d a gene that modifies the severity of lung diseas... condition. The findings open the door to possible...shed study to search the entire genome looking for...
...l Center for Health Care Informatics (NCHCI) Prese... Crossflo Systems, Inc., a Patriot Scientific com...pilot project, created in collaboration with HP an...s, chief executive officer of NCHCI. Mr. Rogers, t...
Other Medicine News:Health News:Cleveland Attorneys Recognized as Ohio Super Lawyers 2Health News:Cleveland Attorneys Recognized as Ohio Super Lawyers 3Health News:Cleveland Attorneys Recognized as Ohio Super Lawyers 4Health News:Sonohysterography is an alternative diagnostic tool for women with adenomyosis 2Health News:IntelliSoft Group Announces Version 9.0 ,Enhancing and Improving IntelliCred Software 2Health News:Brain Adapts to Age-Related Eye Disease 2Health News:Scientists find gene that modifies severity of cystic fibrosis lung disease 2Health News:Scientists find gene that modifies severity of cystic fibrosis lung disease 3Health News:Crossflo Health Information Exchange Project Presented at HP Health and Life Sciences Symposium 2Health News:Crossflo Health Information Exchange Project Presented at HP Health and Life Sciences Symposium 3
...he widest offering of single-use instruments on th...long 43cm lengths for Bariatric Surgery. , Dual a...sulation covers the pivot points to reduce the cha...cord, which eliminates gapping at connection and t...
MultAcoice™™ Rongeur Handle With Ratchet and Monopolar Cautery
MultAcoice™ 5 mm Insulated Outer Shaft
...order products are offered as 1-piece or modular, ...ruments may be customized with handles of choice a...flush ports. Many standard patterns are available ...ffect delivery times. , Please Note: Individual ...
Medicine Products: